Dataset Information

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.

ABSTRACT: BACKGROUND:There is limited data on cerebrospinal fluid (CSF) biomarkers in sporadic amyloid-? (A?) cerebral amyloid angiopathy (CAA). OBJECTIVE:To determine the profile of biomarkers relevant to neurodegenerative disease in the CSF of patients with CAA. METHODS:We performed a detailed comparison of CSF markers, comparing patients with CAA, Alzheimer's disease (AD), and control (CS) participants, recruited from the Biomarkers and Outcomes in CAA (BOCAA) study, and a Specialist Cognitive Disorders Service. RESULTS:We included 10 CAA, 20 AD, and 10 CS participants (mean age 68.6, 62.5, and 62.2 years, respectively). In unadjusted analyses, CAA patients had a distinctive CSF biomarker profile, with significantly lower (p?

SUBMITTER: Banerjee G

PROVIDER: S-EPMC7242825 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.

Banerjee Gargi G Ambler Gareth G Keshavan Ashvini A Paterson Ross W RW Foiani Martha S MS Toombs Jamie J Heslegrave Amanda A Dickson John C JC Fraioli Francesco F Groves Ashley M AM Lunn Michael P MP Fox Nick C NC Zetterberg Henrik H Schott Jonathan M JM Werring David J DJ

Journal of Alzheimer's disease : JAD 20200101 4

<h4>Background</h4>There is limited data on cerebrospinal fluid (CSF) biomarkers in sporadic amyloid-β (Aβ) cerebral amyloid angiopathy (CAA).<h4>Objective</h4>To determine the profile of biomarkers relevant to neurodegenerative disease in the CSF of patients with CAA.<h4>Methods</h4>We performed a detailed comparison of CSF markers, comparing patients with CAA, Alzheimer's disease (AD), and control (CS) participants, recruited from the Biomarkers and Outcomes in CAA (BOCAA) study, and a Special ...[more]

PMID: 32176643

Similar Datasets

Project description:Cerebral amyloid angiopathy (CAA) involves cerebrovascular amyloid deposition and is classified into several types according to the amyloid protein involved. Of these, sporadic amyloid β-protein (Aβ)-type CAA is most commonly found in older individuals and in patients with Alzheimer's disease (AD). Cerebrovascular Aβ deposits accompany functional and pathological changes in cerebral blood vessels (CAA-associated vasculopathies). CAA-associated vasculopathies lead to development of hemorrhagic lesions [lobar intracerebral macrohemorrhage, cortical microhemorrhage, and cortical superficial siderosis (cSS)/focal convexity subarachnoid hemorrhage (SAH)], ischemic lesions (cortical infarction and ischemic changes of the white matter), and encephalopathies that include subacute leukoencephalopathy caused by CAA-associated inflammation/angiitis. Thus, CAA is related to dementia, stroke, and encephalopathies. Recent advances in diagnostic procedures, particularly neuroimaging, have enabled us to establish a clinical diagnosis of CAA without brain biopsies. Sensitive magnetic resonance imaging (MRI) methods, such as gradient-echo T2(*) imaging and susceptibility-weighted imaging, are useful for detecting cortical microhemorrhages and cSS. Amyloid imaging with amyloid-binding positron emission tomography (PET) ligands, such as Pittsburgh Compound B, can detect CAA, although they cannot discriminate vascular from parenchymal amyloid deposits. In addition, cerebrospinal fluid markers may be useful, including levels of Aβ40 for CAA and anti-Aβ antibody for CAA-related inflammation. Moreover, cSS is closely associated with transient focal neurological episodes (TFNE). CAA-related inflammation/angiitis shares pathophysiology with amyloid-related imaging abnormalities (ARIA) induced by Aβ immunotherapies in AD patients. This article reviews CAA and CAA-related disorders with respect to their epidemiology, pathology, pathophysiology, clinical features, biomarkers, diagnosis, treatment, risk factors, and future perspectives.

Dataset Information

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.

Publications

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets